HSBC analyst Rajesh Kumar downgraded Biogen (NASDAQ: BIIB) from Buy to Hold with a price target of $118.00 (from $342.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE